
Rezolute (RZLT) Stock Forecast & Price Target
Rezolute (RZLT) Analyst Ratings
Bulls say
Rezolute Inc's incremental growth in research and development (R&D) expenses of 4.9% year-over-year, aligning closely with their clinical advancement initiatives, suggests a commitment to innovation and a robust pipeline, particularly with the upcoming Phase 3 study of ersodetug. The company’s narrower-than-expected loss of $0.22 per share in F2Q25, which was better than both internal estimates and market consensus, indicates improved operational efficiency and potential for future profitability. Additionally, the Breakthrough Therapy Designation awarded in January is expected to facilitate quicker patient enrollment in clinical trials, enhancing the likelihood of successful outcomes for its pipeline products RZ358 and RZ402.
Bears say
Rezolute Inc reported a loss per share of $0.27 for fiscal second quarter 2024, indicating a challenging financial position. The enrollment criteria for the sunRIZE Phase 3 study present significant hurdles, including high screen failure rates of 35-40%, which could adversely affect trial outcomes and the overall product pipeline. Additionally, concerns regarding the lower expected placebo response rates may further complicate the analysis and market perception of the company's development efforts, contributing to a cautious outlook for the stock.
This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.
Rezolute (RZLT) Analyst Forecast & Price Prediction
Start investing in Rezolute (RZLT)
Order type
Buy in
Order amount
Est. shares
0 shares